Brokerage Firm Rating on Charles River Laboratories International (CRL)

Charles River Laboratories International (CRL) : 14 analysts are covering Charles River Laboratories International (CRL) and their average rating on the stock is 2, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Charles River Laboratories International (CRL) : 9 Wall Street analysts covering Charles River Laboratories International (CRL) believe that the average level the stock could reach for the short term is $89. The maximum price target given is $100 and the minimum target for short term is around $65, hence the standard deviation is calculated at $10.89.


For the current week, the company shares have a recommendation consensus of Buy. Charles River Laboratories International (NYSE:CRL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $83.26 and $82.45 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $83.58. The buying momentum continued till the end and the stock did not give up its gains. It closed at $83.27, notching a gain of 0.17% for the day. The total traded volume was 327,036 . The stock had closed at $83.13 on the previous day.

In a related news, Wallman Richard F, director of Charles River Laboratories International Inc, unloaded 7,740 shares at an average price of $88 on July 29, 2016. The total amount of the transaction was worth $681,120, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Charles River Laboratories International, Inc. is a full service, early stage contract research company. The Company offers research models for the research and development of new drugs, devices and therapies. It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS), which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides services that enables the clients to outsource their drug discovery research, critical, regulatory-required safety assessment testing and related drug discovery and development activities, and Manufacturing Support (Manufacturing), which is involved in the production and release of products manufactured by the clients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.